Tag: siRNA
-
The TTR silencers — siRNA vutrisiran succeeded, ASO eplontersen missed, but the deciding variable was the trial population, not the modality
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. All knockdown, hazard-ratio and subgroup figures are attributed to the sponsoring trial, journal or company; several eplontersen numbers are a company press release rather than peer-reviewed data (noted inline), with…
Uthando Nethemba 